[go: up one dir, main page]

US20130096063A1 - Hemostatic compositions - Google Patents

Hemostatic compositions Download PDF

Info

Publication number
US20130096063A1
US20130096063A1 US13/648,902 US201213648902A US2013096063A1 US 20130096063 A1 US20130096063 A1 US 20130096063A1 US 201213648902 A US201213648902 A US 201213648902A US 2013096063 A1 US2013096063 A1 US 2013096063A1
Authority
US
United States
Prior art keywords
hemostatic composition
polymer
composition according
hemostatic
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/648,902
Other languages
English (en)
Inventor
Hans Christian Hedrich
Joris Hoefinghoff
Katarzyna Gorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US13/648,902 priority Critical patent/US20130096063A1/en
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOEFINGHOFF, JORIS, GORNA, KATARZYNA, HEDRICH, HANS CHRISTIAN
Publication of US20130096063A1 publication Critical patent/US20130096063A1/en
Priority to US15/004,520 priority patent/US9821025B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to hemostatic compositions and processes for making such compositions.
  • Hemostatic compositions in dry storage-stable form that comprise biocompatible, biodegradable, dry stable granular material are known e.g. from WO98/008550A or WO 2003/007845A. These products have been successfully applied on the art for hemostasis.
  • Floseal® is an example for a powerful and versatile hemostatic agent consisting of a granular gelatin matrix swollen in a thrombin-containing solution to form a flowable paste.
  • the present invention provides a hemostatic composition comprising:
  • crosslinking reaction Upon contact with bleeding tissue, a crosslinking reaction of the hydrophilic polymeric component with the blood proteins leads to formation of a gel with sealing and hemostatic properties. Crosslinking also occurs to the tissue surface proteins and, depending on the nature of the biocompatible polymer material, may also occur to the biocompatible polymer material. The latter reaction contributes to an improved adhesion of the composition material to the wounded tissue surface.
  • a further aspect relates to a method of treating an injury comprising administering a hemostatic composition to the site of injury.
  • kits for the treatment of an injury comprising a hemostatic composition as herein disclosed and instructions for use.
  • the present invention also refers to a method for producing the hemostatic composition according to the invention in a convenient manner allowing the composition to be easily at hand for medical use.
  • the invention further relates to a method for delivering a hemostatic composition to a target site in a patient's body, said method comprising delivering a hemostatic composition produced by the process of the present invention to the target site.
  • the present invention relates to a finished final container obtained by the process according of the present invention containing the present hemostatic composition.
  • the invention also relates to a method for providing a ready-to-use hemostatic composition
  • a method for providing a ready-to-use hemostatic composition comprising contacting a hemostatic composition produced by the process of the present invention with a pharmaceutically acceptable diluent as well as to a kit comprising the finished final container and other means for applying the composition (e.g. a diluent container).
  • the compositions according to the present invention are particularly useful for providing hemostasis at bleeding sites, including surgical bleeding sites, traumatic bleeding sites and the like.
  • An exemplary use of the compositions may be in sealing the tissue tract above a blood vessel penetration created for vascular catheterization.
  • the biocompatible polymers in particulate form suitable for use in hemostasis may include dimensionally isotropic or non-isotropic forms.
  • the biocompatible polymers according to the present invention may be granules or fibers; and may be present in discontinuous structures, for example in powder forms.
  • the biocompatible polymer and the hydrophilic polymeric component are present in dry form, preferably in mixed dry form.
  • Suitable biologic polymers include polysaccharides, such as glycosaminoglycans, starch, cellulose, dextran, hemicellulose, xylan, agarose, alginate and chitosan; and derivatives and combinations thereof.
  • Suitable non-biologic polymers will be selected to be degradable by either of two mechanisms, i.e. (1) break down of the polymeric backbone or (2) degradation of side chains which result in aqueous solubility.
  • non-biologic biocompatible polymers suitable for use in hemostasis include synthetics, such as polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyethyleneimines, polyvinyl resins, polylactide-glycolides, polycaprolactones, and polyoxyethlenes; and derivatives and combinations thereof. Also combinations of different kinds of polymers are possible (e.g. proteins with polysaccharides, proteins with non-biologic hydrogel-forming polymers, etc.).
  • Preferred hemostatic polymers comprise amino-groups, specifically if the hydrophilic polymeric component has reactive groups which react with amino-groups upon administration (e.g. in the wound environment).
  • crosslinking may be achieved by using oxidizers and other agents, such as periodates, which activate side-chains or moieties on the polymer so that they may react with other side-chains or moieties to form the crosslinking bonds.
  • An additional method of crosslinking comprises exposing the polymers to radiation, such as gamma radiation, to activate the polymer chains to permit crosslinking reactions.
  • Dehydrothermal crosslinking methods may also be suitable. Preferred methods for crosslinking gelatin molecules are described below.
  • the pH should be held from about 6 to 11, preferably from 7 to 10.
  • the crosslinks are formed via Schiff bases which may be stabilized by subsequent reduction, e.g., by treatment with sodium borohydride.
  • the resulting granules may be washed in water and optionally rinsed in an alcohol, and dried. The resulting dry powders may then be provided in the final container as described herein.
  • powders are defined herein as a special sub-class of granular materials.
  • powders refer to those granular materials that have the finer grain sizes, and that therefore have a greater tendency to form clumps when flowing.
  • Granules include coarser granular materials that do not tend to form clumps except when wet.
  • the particles used are those which can be coated by suitable coating techniques Particle size of the polymer granules according to the present invention can therefore easily be adapted and optimized to a certain coating technique by the necessities of this technique.
  • the hydrophilic reactive polymer has the ability to crosslink blood proteins and also tissue surface proteins. Crosslinking to the biomaterial is also possible.
  • the hydrophilic crosslinker according to the present invention is a polymer, i.e. a large molecule (macromolecule) composed of repeating structural units which are typically connected by covalent chemical bonds.
  • the hydrophilic polymer component according to the present invention should have a molecular weight of at least 1000 Da (to properly serve as crosslinker in the hemostatic composition according to the present invention); preferably the crosslinking polymers according to the present invention has a molecular weight of at least 5000 Da, especially of at least 8000 Da.
  • hydrophilic crosslinkers For some hydrophilic crosslinkers, the presence of basic reaction conditions (e.g. at the administration site) is preferred or necessary for functional performance (e.g. for a faster crosslinking reaction at the administration site).
  • carbonate or bicarbonate ions e.g. as a buffer with a pH of 7.6 or above, preferably of 8.0 or above, especially of 8.3 and above
  • may be additionally provided at the site of administration e.g. as a buffer solution or as a fabric or pad soaked with such a buffer), so as to allow an improved performance of the hemostatic composition according to the present invention or to allow efficient use as a hemostatic and/or wound adherent material.
  • the hemostatic compositions according to the present invention are preferably provided as dry composition, e.g. as a physical mixture, of the hemostatic polymer and the hydrophilic reactive component, wherein the biocompatible polymer and the hydrophilic polymeric component are present in dry form, preferably in mixed dry form.
  • “Mixed” according to the present invention includes powder mixing, coating, impregnating, blending, agglomerating, co-lyophilizing, drying from suspension, subsequent or concurrent co-filling, co-extruding, etc.
  • a “dry” hemostatic composition according to the present invention has only a residual content of moisture which may approximately correspond to the moisture content of comparable available products, such as Floseal® (Floseal, for example, has about 12% moisture as a dry product).
  • the dry composition according to the present invention has a residual moisture content below these products, preferably below 10% moisture, more preferred below 5% moisture, more preferred below 2.5%, especially below 1% moisture.
  • the hemostatic composition according to the present invention can also have lower moisture content, e.g. 0.1% or even below.
  • Preferred moisture contents of the dry hemostatic composition according to the present invention are 0.1 to 10%, especially 0.5 to 5%. It is clear that the dryer the composition is, the longer their shelf life is and the lower is the risk that the hemostatic properties of the composition as a whole suffer.
  • the biocompatible polymer in particulate form suitable for use in hemostasis is preferably gelatin in powder form, especially wherein the powder particles have a median particle size of 10 to 1000 ⁇ m, preferably from 50 to 750 ⁇ m, more preferred from 150 to 700 ⁇ m, especially from 150 to 500 ⁇ m.
  • the hemostatic compositions according to the present invention may further comprise a substance selected from the group consisting of antifibrinolytic, procoagulant, platelet activator, antibiotic, vasoconstrictor, dye, growth factors, bone morphogenetic proteins and pain killers.
  • the hemostatic composition according to the present invention may comprise a further composition of gelatin and a polyvalent nucelophilic substance, preferably human serum albumin, optionally at a basic pH (e.g. pH 8 to 11, preferably 9 to 10, especially at a pH of 9.5).
  • a basic pH e.g. pH 8 to 11, preferably 9 to 10, especially at a pH of 9.5.
  • the 2 components may then be co-applied to an injury.
  • the present invention also relates to a method for producing a hemostatic composition according to the present invention comprising the step of mixing, a biocompatible polymer suitable for use in hemostasis and one hydrophilic polymeric component comprising reactive groups in dry form.
  • hemostatic compositions according to the present invention in dry form in an administration container, preferably in a syringe, optionally together with a pharmaceutically acceptable diluent.
  • such products are usually provided in a dry form and brought into the “ready-to-use” form (which is usually in the form of a (hydro-)gel, suspension or solution) immediately before use, necessitating the addition of wetting or solvation (suspension) agents.
  • the hemostatic composition is provided in dry form in the final container.
  • degradation or inactivation processes for the components are significantly and appropriately reduced to enable storage stability.
  • a suitable diluent comprises water for injection, and—independently of each other—50 to 200 mM NaCl (preferably 150 mM), 10 to 80 mM CaCl 2 (preferably 40 mM) and 1 to 50 mM sodium acetate (preferably 20 mM).
  • the diluent can also include a buffer or buffer system so as to buffer the pH of the reconstituted dry composition, preferably at a pH of 3.0 to 10.0, more preferred of 6.4 to 7.5, especially at a pH of 8.9 to 7.1.
  • the thrombin preparation contains human albumin.
  • Preferred salts are NaCl and/or CaCl 2 , both used in the usual amounts and concentrations applied for thrombin (e.g. 0.5 to 1.5% NaCl (e.g. 0.9%) and/or 20 to 80 mM CaCl 2 (e.g. 40 mM)).
  • the pharmaceutically acceptable diluent is provided In a separate container.
  • This can preferably be a syringe.
  • the diluent in the syringe can then easily be applied to the final container for reconstitution of the dry hemostatic compositions according to the present invention. If the final container is also a syringe, both syringes can be finished together in a pack. It is therefore preferred to provide the dry hemostatic compositions according to the present invention in a syringe which is finished with a diluent syringe with a pharmaceutically acceptable diluent for reconstituting said dry and stable hemostatic composition.
  • the final container further contains an amount of a stabilizer effective to inhibit modification of the polymer when exposed to the sterilizing radiation, preferably ascorbic acid, sodium ascorbate, other salts of ascorbic acid, or an antioxidant.
  • a stabilizer effective to inhibit modification of the polymer when exposed to the sterilizing radiation, preferably ascorbic acid, sodium ascorbate, other salts of ascorbic acid, or an antioxidant.
  • the present invention also provides a method for delivering a hemostatic composition according to the invention to a target site in a patient's body, said method comprising delivering a hemostatic composition produced by the process according to the present invention to the target site.
  • the dry composition can be directly applied to the target site (and, optionally be contacted with the diluent a the target site, if necessary), it is preferred to contact the dry hemostatic composition with a pharmaceutically acceptable diluent before administration to the target site, so as to obtain a hemostatic composition in a wetted form, especially a hydrogel form.
  • the present invention also refers to a finished final container obtained by the process according to the present invention.
  • This finished container contains the combined components in a sterile, storage-stable and marketable form.
  • the final container can be any container suitable for housing (and storing) pharmaceutically administrable compounds.
  • Syringes, vials, tubes, etc. can be used; however, providing the hemostatic compositions according to the present invention in a syringe is specifically preferred.
  • Syringes have been a preferred administration means for hemostatic compositions as disclosed in the prior art also because of the handling advantages of syringes in medical practice.
  • the compositions may then preferably be applied (after reconstitution) via specific needles of the syringe or via suitable catheters.
  • the reconstituted hemostatic compositions (which are preferably reconstituted to form a hydrogel) may also be applied by various other means e.g. by a spatula, a brush, a spray, manually by pressure, or by any other conventional technique. Administration of the reconstituted hemostatic composition to a patient by spraying is specifically preferred.
  • the reconstituted hemostatic compositions according to the present invention will be applied using a syringe or similar applicator capable of extruding the reconstituted composition through an orifice, aperture, needle, tube, or other passage to form a bead, layer, or similar portion of material.
  • the hemostatic compositions can be performed by extrusion through an orifice in the syringe or other applicator, typically having a size in the range from 0.01 mm to 5.0 mm, preferably 0.5 mm to 2.5 mm.
  • the hemostatic composition will be initially prepared from a dry form having a desired particle size (which upon reconstitution, especially by hydration, yields subunits of the requisite size (e.g. hydrogel subunits)) or will be partially or entirely mechanically disrupted to the requisite size prior to a final extrusion or other application step. It is, of course evident, that these mechanical components have to be provided in sterile form (inside and outside) in order to fulfill safety requirements for human use.
  • Another aspect of the invention concerns a method for providing a ready-to-use hemostatic composition comprising contacting a hemostatic composition produced by the process according to the present invention with a pharmaceutically acceptable diluent.
  • This process provides a suitable “ready-to-use” form of the compositions according to the present invention which can easily and efficiently be made also within short times, eg. in emergency situations during surgery.
  • This flowable form of the hemostatic composition provided by such a method is specifically suitable for use in the treatment of an injury selected from the group consisting of a wound, a hemorrhage, damaged tissue, bleeding tissue and/or bone defects.
  • FIG. 1 shows crosslinked gelatin mixed with 20 wt % of NHS-PEG hydrated with saline solution at neutral pH (Example 1) in a liver punch lesion model 5 min post application.
  • Example 1 In order to obtain a faster reactive flowable hemostat the mixture as described in Example 1 was hydrated by using 3.5 ml of a basic buffer having pH of 9.5 as a diluent.
  • a product obtained was allowed to hydrate for 2 minutes and was applied to a blending wound.
  • Example 1 In order to obtain a reactive flowable hemostat with prolonged stability the mixture as described in Example 1 was hydrated with 3.5 ml of saline solution having pH adjusted to 1.5 with 1 M of HCl as a diluent.
  • Example 1 A preparation of Example 1 was tested for hemostatic efficacy on heparinized animal (pig) in a punch or biopsy liver lesion. Each lesion in the series was topically treated with the product applied from the syringe through applicator tip. Moistened gauze was used to help approximate the test product to the lesion and the timer was started. A saline moistened approximation gauze was removed after 30 seconds and the degree of bleeding was assessed at 30 seconds, 1, 2, 5 and 10 minutes after the test articles were applied. Product saturated with blood but without active bleeding was scored as 0. Saline solution was used to irrigate the excess test articles away from the lesions after the 5 minutes assessment. Performance of selected formulations at 5 minutes assessment is shown in FIG. 1 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers & Plastics (AREA)
US13/648,902 2011-10-11 2012-10-10 Hemostatic compositions Abandoned US20130096063A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/648,902 US20130096063A1 (en) 2011-10-11 2012-10-10 Hemostatic compositions
US15/004,520 US9821025B2 (en) 2011-10-11 2016-01-22 Hemostatic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545909P 2011-10-11 2011-10-11
US13/648,902 US20130096063A1 (en) 2011-10-11 2012-10-10 Hemostatic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/004,520 Continuation US9821025B2 (en) 2011-10-11 2016-01-22 Hemostatic compositions

Publications (1)

Publication Number Publication Date
US20130096063A1 true US20130096063A1 (en) 2013-04-18

Family

ID=47018202

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/648,902 Abandoned US20130096063A1 (en) 2011-10-11 2012-10-10 Hemostatic compositions
US15/004,520 Active US9821025B2 (en) 2011-10-11 2016-01-22 Hemostatic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/004,520 Active US9821025B2 (en) 2011-10-11 2016-01-22 Hemostatic compositions

Country Status (11)

Country Link
US (2) US20130096063A1 (fr)
EP (2) EP2766059B1 (fr)
JP (2) JP6195569B2 (fr)
KR (1) KR102102002B1 (fr)
CN (1) CN103957949B (fr)
AU (1) AU2012318257B2 (fr)
CA (1) CA2851321C (fr)
ES (1) ES2938568T3 (fr)
IL (1) IL231961A0 (fr)
MX (1) MX356185B (fr)
WO (1) WO2013053759A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210001002A1 (en) * 2017-11-28 2021-01-07 Dalim Tissen Co., Ltd. Composition for hemostasis and container comprising same
CN114096285A (zh) * 2019-07-12 2022-02-25 加特技术公司 生物相容性柔性止血片
CN115944771A (zh) * 2022-12-27 2023-04-11 合肥工业大学 一种具有强效湿粘附与止血功能的仿生止血糊剂及其制备方法
EP3989875A4 (fr) * 2019-06-26 2023-07-26 Davol Inc. Matériaux hémostatiques pulvérulents secs réactifs comprenant un nucléophile et un agent de réticulation à base de polyéthylène glycol modifié multifonctionnel
US12070522B2 (en) 2020-02-18 2024-08-27 Ethicon, Inc. Melt blown dressing with gradient density
US12102722B2 (en) 2020-06-08 2024-10-01 Ethicon, Inc. Napped coated wound dressing
US12151045B2 (en) 2020-12-28 2024-11-26 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US12324866B2 (en) 2019-07-12 2025-06-10 Gatt Technologies B.V. Method for preparing a tissue-adhesive sheet
US12440600B2 (en) 2019-07-12 2025-10-14 Cilag Gmbh International Biocompatible, flexible, haemostatic sheet

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716872C (fr) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Dispositif pour la promotion de l'homeostasie et/ou la cicatrisation des plaies
CN103998068B (zh) * 2011-10-11 2016-05-25 巴克斯特国际公司 止血组合物
MX346958B (es) * 2011-10-11 2017-04-06 Baxter Int Composición hemostatica.
IN2014DN08122A (fr) 2012-03-06 2015-05-01 Ferrosan Medical Devices As
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
JP6390873B2 (ja) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー／エス 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ
CA2928963C (fr) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Composition seche comprenant un ameliorateur d'extrusion
CA2960309A1 (fr) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Composition seche destinee a etre utilisee en hemostase et cicatrisation de plaie
EP3237041B1 (fr) 2014-12-24 2020-01-29 Ferrosan Medical Devices A/S Seringue pour la retention et le mélange de premières et secondes substances
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN105521521B (zh) * 2015-12-17 2018-10-30 杭州亚慧生物科技有限公司 一种肺部封合医用凝胶及其制备方法与应用
CN107349462B (zh) * 2016-05-09 2020-07-14 北京纳什国际生物科技有限公司 一种可吸收半流动性交联多肽生物外科止血物
KR20180027126A (ko) 2016-09-06 2018-03-14 (주)한국비엠아이 가교화 히알루론산 유도체 매트릭스가 포함된 지혈 조성물
CN108498879B (zh) 2017-02-28 2021-12-28 苏州安德佳生物科技有限公司 黏膜下注射用组合物和试剂组合及其应用
US20210128778A1 (en) * 2017-03-09 2021-05-06 Baxter International Inc. Solvent deposition system and methods
CN110691615A (zh) * 2017-04-28 2020-01-14 库克医学技术有限责任公司 具有活动性出血的胃肠道病损的双峰治疗方法和组合物
CN110025821A (zh) * 2018-01-12 2019-07-19 北京环球利康科技有限公司 使用生物相容性止血剂和组织封闭剂的组合物处理活动性出血的方法
EP3790600B1 (fr) 2018-05-09 2023-12-27 Ferrosan Medical Devices A/S Procédé de préparation d'une composition hémostatique
US20210236642A1 (en) * 2018-07-26 2021-08-05 Srinivas Reddy Male Haemostatic gel composition and its process of preparation
US20220016311A1 (en) * 2018-12-14 2022-01-20 Bmg Incorporated Two-reactant sheet-shaped adhesive/reinforcement for tissues
EP3996758B1 (fr) * 2019-07-12 2023-07-26 Cilag GmbH International Poudre hémostatique
CN115025274B (zh) * 2021-03-04 2023-03-17 海宁侏罗纪生物科技有限公司 一种医用组织粘合胶及其制备方法
CN115252875B (zh) * 2021-04-29 2023-06-16 浙江大学 一种医用组织粘合胶及其制备方法
CN113209357B (zh) * 2021-05-14 2023-02-17 南方科技大学 复合止血粉
CN113599568A (zh) * 2021-08-05 2021-11-05 南方科技大学 合成材料类粉剂及其在止血体系的应用
WO2023097148A1 (fr) 2021-11-29 2023-06-01 Baxter International Inc. Procédés et dispositifs améliorés de reconstitution d'hémostat

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569193A (en) * 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US6458147B1 (en) * 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
WO2003007845A1 (fr) * 2001-07-17 2003-01-30 Baxter International Inc. Compositions hemostatiques seches et procedes de preparation associes
US20030129730A1 (en) * 2001-11-15 2003-07-10 Abdellatif Chenite Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US20040214770A1 (en) * 1996-08-27 2004-10-28 Fusion Medical Technologies, Inc. Hemoactive compositions and methods for their manufacture and use
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
US20060258560A1 (en) * 2002-09-30 2006-11-16 Chunlin Yang Dry tissue sealant compositions
US20080187591A1 (en) * 2006-08-02 2008-08-07 Baxter International, Inc. Rapidly acting dry sealant and methods for use and manufacture

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507244A (en) 1947-04-14 1950-05-09 Upjohn Co Surgical gelatin dusting powder and process for preparing same
CH264752A (de) 1947-06-03 1949-10-31 Hoffmann La Roche Verfahren zur Herstellung von Trägern für Arzneimittel.
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
SE420565B (sv) 1974-06-06 1981-10-19 Pharmacia Ab Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel
US4013078A (en) 1974-11-25 1977-03-22 Feild James Rodney Intervertebral protector means
JPS5823410B2 (ja) 1974-11-12 1983-05-14 株式会社クラレ ヒドロゲルヨウキザイ
US4006220A (en) 1975-06-04 1977-02-01 Gottlieb Sheldon K Compositions and methods useful for repairing depressed cutaneous scars
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2843963A1 (de) 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
US4265233A (en) 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
US4179400A (en) 1978-05-09 1979-12-18 W. R. Grace & Co. Process for preparing catalytic solutions of sulfonium salts
AT359653B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
AT359652B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
DE3036033A1 (de) 1980-09-24 1982-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Wundbehandlungsmittel in pulverform und verfahren zu seiner herstellung
US4300494A (en) 1979-09-26 1981-11-17 Shell Oil Company Thermal insulated intake ports
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
DE3105624A1 (de) 1981-02-16 1982-09-02 Hormon-Chemie München GmbH, 8000 München Material zum abdichten und heilen von wunden
US4424208A (en) 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4482386A (en) 1982-03-26 1984-11-13 Warner-Lambert Company Method of conditioning a water swellable hydrocolloid
US4543332A (en) 1982-03-29 1985-09-24 Miles Laboratories, Inc. Method for the preparation of spherical microorganism cell aggregates
US4540410A (en) 1982-11-16 1985-09-10 Serono Pharmaceutical Partners Lyophilized compositions, preparation and use thereof
JPS59113889A (ja) 1982-12-17 1984-06-30 Sumitomo Chem Co Ltd 固定化酵素もしくは固定化微生物菌体の製造方法
DE3466702D1 (en) 1983-07-14 1987-11-12 Hitachi Chemical Co Ltd Gelatin spherical gels and production thereof
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4515637A (en) 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4600574A (en) 1984-03-21 1986-07-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of producing a tissue adhesive
US4837285A (en) 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
SE456346B (sv) 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
JPS6144825A (ja) 1984-08-09 1986-03-04 Unitika Ltd 止血剤
GB8422950D0 (en) 1984-09-11 1984-10-17 Warne K J Hydrogel
JPS61122222A (ja) 1984-11-19 1986-06-10 Koken:Kk コラ−ゲン又はゼラチンとプロタミンとよりなる止血剤
US5178883A (en) 1984-11-29 1993-01-12 Regents Of The University Of Minnesota Method for promoting hair growth
US5165938A (en) 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US4600533A (en) 1984-12-24 1986-07-15 Collagen Corporation Collagen membranes for medical use
US5007916A (en) 1985-08-22 1991-04-16 Johnson & Johnson Medical, Inc. Method and material for prevention of surgical adhesions
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
IL78826A (en) 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
US4946870A (en) 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US5300494A (en) 1986-06-06 1994-04-05 Union Carbide Chemicals & Plastics Technology Corporation Delivery systems for quaternary and related compounds
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4803075A (en) 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
US4885161A (en) 1987-03-11 1989-12-05 Medi-Tech International Corporation Wound dressings in gelled paste form
CA1305069C (fr) 1987-03-11 1992-07-14 John Cornell Pansement en feuille ou en gelee
US5080893A (en) 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5350573A (en) 1988-05-31 1994-09-27 University Of Florida Research Foundation, Inc. Method and composition for preventing surgical adhesions
US5140016A (en) 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US5447966A (en) 1988-07-19 1995-09-05 United States Surgical Corporation Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5041292A (en) 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5135751A (en) 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US4891359A (en) 1988-12-08 1990-01-02 Johnson & Johnson Patient Care, Inc. Hemostatic collagen paste composition
DE3903672C1 (fr) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
KR910007847B1 (ko) 1989-06-10 1991-10-02 한국과학기술원 스폰지 구조를 갖는 새로운 다공성 젤라틴 미립 담체 및 그 제조방법
CA2051638A1 (fr) 1989-08-10 1991-02-11 John Richard Hull Systeme de dispensation medicale d'adhesifs tissulaires
US5196185A (en) 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
US5061274A (en) 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
US5219328A (en) 1990-01-03 1993-06-15 Cryolife, Inc. Fibrin sealant delivery method
US5134229A (en) 1990-01-12 1992-07-28 Johnson & Johnson Medical, Inc. Process for preparing a neutralized oxidized cellulose product and its method of use
JPH0813750B2 (ja) 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
US5306501A (en) 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5595735A (en) 1990-05-23 1997-01-21 Johnson & Johnson Medical, Inc. Hemostatic thrombin paste composition
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
US5292362A (en) 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5209776A (en) 1990-07-27 1993-05-11 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5192300A (en) 1990-10-01 1993-03-09 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5108421A (en) 1990-10-01 1992-04-28 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5129882A (en) 1990-12-27 1992-07-14 Novoste Corporation Wound clotting device and method of using same
US5690675A (en) 1991-02-13 1997-11-25 Fusion Medical Technologies, Inc. Methods for sealing of staples and other fasteners in tissue
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2089487A1 (fr) 1991-06-14 1992-12-15 Suk-Zu Song Presentation du produit par pellicule de collagene pour proteines
NL9101051A (nl) 1991-06-18 1993-01-18 Ashridge Ag Sluitinrichting voor een bloedvat of dergelijke.
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
DK0632820T3 (da) 1992-02-28 2000-10-02 Collagen Corp Højkoncentrerede, homogeniserede collagensammensætninger
US5468505A (en) 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
CA2128783C (fr) 1992-02-28 2004-10-12 Donald G. Wallace Compositions de ceramique injectable et methodes de preparation et d'utilisation connexes
US5204382A (en) 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
US5384333A (en) 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
JPH07506991A (ja) 1992-04-23 1995-08-03 シメッド　ライフ　システムズ　インコーポレイテッド 血管穿刺を密封するための装置及び方法
IL105529A0 (en) 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
JPH05308969A (ja) 1992-05-13 1993-11-22 Japan Vilene Co Ltd 酵素保持体及びその製造方法
WO1993024476A1 (fr) 1992-06-04 1993-12-09 Clover Consolidated, Limited Vehicules polymeres solubles dans l'eau servant a la liberation de medicaments
US5385606A (en) 1992-07-06 1995-01-31 Kowanko; Nicholas Adhesive composition and method
US5413571A (en) 1992-07-16 1995-05-09 Sherwood Medical Company Device for sealing hemostatic incisions
US5428022A (en) 1992-07-29 1995-06-27 Collagen Corporation Composition of low type III content human placental collagen
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
DE4227681C2 (de) 1992-08-21 1995-05-18 Becker & Co Naturinwerk Wundabdeckungsmaterial auf der Basis von Kollagenfasern und Verfahren zu seiner Herstellung
AU5600294A (en) 1992-11-12 1994-06-08 Neville Alleyne Cardiac protection device
US5667839A (en) 1993-01-28 1997-09-16 Collagen Corporation Human recombinant collagen in the milk of transgenic animals
JPH08131B2 (ja) 1993-03-05 1996-01-10 新田ゼラチン株式会社 止血用パッド
JP3639593B2 (ja) 1993-05-31 2005-04-20 科研製薬株式会社 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
JPH0790241A (ja) 1993-09-22 1995-04-04 Menicon Co Ltd 眼用レンズ材料用仮接着剤
JPH09504719A (ja) 1993-11-03 1997-05-13 クラリオン、ファーマシューティカルズ、インコーポレイテッド 止血パッチ
FR2715309B1 (fr) 1994-01-24 1996-08-02 Imedex Composition adhésive, à usage chirurgical, à base de collagène modifié par coupure oxydative et non réticulé.
US5674275A (en) 1994-04-06 1997-10-07 Graphic Controls Corporation Polyacrylate and polymethacrylate ester based hydrogel adhesives
US5531759A (en) 1994-04-29 1996-07-02 Kensey Nash Corporation System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating
JP3107726B2 (ja) 1994-05-13 2000-11-13 株式会社クラレ 水膨潤性高分子ゲル
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
GB9415739D0 (en) 1994-07-30 1994-09-21 Scimat Ltd Gel wound dressing
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5931165A (en) 1994-09-06 1999-08-03 Fusion Medical Technologies, Inc. Films having improved characteristics and methods for their preparation and use
WO1996010374A1 (fr) 1994-10-03 1996-04-11 Otogen Corporation Implants biomedicaux a biodegradabilite differentielle
FR2726571B1 (fr) 1994-11-03 1997-08-08 Izoret Georges Colle biologique, procede de preparation et dispositif d'application pour colle biologique, et durcisseurs pour colle biologique
US20030039695A1 (en) 2001-08-10 2003-02-27 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Collagen carrier of therapeutic genetic material, and method
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5580923A (en) 1995-03-14 1996-12-03 Collagen Corporation Anti-adhesion films and compositions for medical use
US5677284A (en) 1995-06-06 1997-10-14 Regen Biologics, Inc. Charged collagen particle-based delivery matrix
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
DK1704878T3 (da) 1995-12-18 2013-07-01 Angiodevice Internat Gmbh Tværbundne polymerpræparater og fremgangsmåder til deres anvendelse
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US5752974A (en) 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US5748318A (en) 1996-01-23 1998-05-05 Brown University Research Foundation Optical stress generator and detector
US5782917A (en) 1996-02-26 1998-07-21 Sunmed, Inc. Intramedullary bone plug
CA2251475C (fr) 1996-04-04 2006-09-05 Immuno Aktiengesellschaft Eponge hemostatique a base de collagene
US6132759A (en) 1996-05-03 2000-10-17 Innogenetics N.V. Medicaments containing gelatin cross-linked with oxidized polysaccharides
WO1997044015A1 (fr) * 1996-05-17 1997-11-27 Andaris Limited Microparticules et utilisation de ces dernieres pour soigner des plaies
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
US5902832A (en) 1996-08-20 1999-05-11 Menlo Care, Inc. Method of synthesizing swollen hydrogel for sphincter augmentation
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US6706690B2 (en) 1999-06-10 2004-03-16 Baxter Healthcare Corporation Hemoactive compositions and methods for their manufacture and use
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
ES2243000T3 (es) 1997-06-03 2005-11-16 Innogenetics N.V. Nuevos medicamentos basados en polimeros compuestos de gelatina modificada con metacrilamina.
US5908054A (en) 1997-06-16 1999-06-01 Fusion Medical Technologies, Inc. Fluid dispersion and delivery assembly and method
AU743039B2 (en) 1997-09-16 2002-01-17 Integra Lifesciences Corporation Product for promoting dural or meningeal tissue growth comprising collagen
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
US6179872B1 (en) 1998-03-17 2001-01-30 Tissue Engineering Biopolymer matt for use in tissue repair and reconstruction
US6110484A (en) 1998-11-24 2000-08-29 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
US6328229B1 (en) 1998-12-18 2001-12-11 Cohesion Technologies, Inc. Low volume mixing spray head for mixing and dispensing of two reactive fluid components
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
WO2001016210A1 (fr) 1999-08-27 2001-03-08 Cohesion Technologies, Inc. Compositions formant des reseaux de polymeres interpenetrants, a utiliser en tant produits de scellement medicaux a haute resistance
US6221109B1 (en) 1999-09-15 2001-04-24 Ed. Geistlich Söhne AG fur Chemische Industrie Method of protecting spinal area
US6312474B1 (en) 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
CN1114728C (zh) 2000-04-21 2003-07-16 中国石油化工集团公司 止血纤维及其制造方法
JP2004508137A (ja) 2000-09-12 2004-03-18 ヴァージニア　コモンウェルス　ユニバーシティ 高圧出血に対する処置
MXPA03002414A (es) 2000-09-18 2004-07-08 Organogenesis Inc Protesis con injerto de hoja plana tratada por bioingenieria y su uso.
EP1547626A3 (fr) 2001-01-25 2009-07-29 Nycomed Pharma AS Support a fibrinogene et thrombine solides
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
JP2006523113A (ja) * 2003-04-04 2006-10-12 ティシュームド リミテッド 組織接着構成物
DE102004027363A1 (de) 2003-06-05 2005-01-27 Baxter Healthcare S.A. Verfahren zur Reparatur und zur Regeneration menschlicher Dura Mater
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
WO2005046516A2 (fr) 2003-11-10 2005-05-26 Angiotech International Ag Implants médicaux et agents anti-cicatrisation
WO2006031358A2 (fr) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Polymeres dendritiques, gels reticules, et leurs utilisations comme agents de scellement et lentilles ophtalmiques
US20080091277A1 (en) 2004-08-13 2008-04-17 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
US8246990B2 (en) 2005-05-04 2012-08-21 Suprapolix B.V. Hydrogen bonded hydrogels
WO2007001926A2 (fr) 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Matériaux d'obturation par hydrogel à faible gonflement pour la réparation des blessures
ES2575933T3 (es) 2006-05-31 2016-07-04 Baxter International Inc. Colágeno para su uso en la prevención de la formación de fibrosis epidural después de cirugía espinal
CA2703103C (fr) 2007-10-30 2017-05-09 Baxter Healthcare S.A. Utilisation de biomatrice de collagene biofonctionnelle renegeratrice permettant de traiter des lesions parietales ou viscerales
DE102008005469A1 (de) 2008-01-21 2009-07-23 Kettenbach Gmbh & Co. Kg Pastöses Einsetzmaterial zur Erweiterung des Zahnfleischsulcus und dessen Verwendung
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
US9162006B2 (en) * 2009-06-16 2015-10-20 Baxter International Inc. Hemostatic sponge
EP2575775B1 (fr) * 2010-06-01 2018-04-04 Baxter International Inc. Procédé de fabrication de compositions hémostatiques sous forme sèche et stable
MX346958B (es) * 2011-10-11 2017-04-06 Baxter Int Composición hemostatica.
CN103998068B (zh) 2011-10-11 2016-05-25 巴克斯特国际公司 止血组合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5569193A (en) * 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US20040214770A1 (en) * 1996-08-27 2004-10-28 Fusion Medical Technologies, Inc. Hemoactive compositions and methods for their manufacture and use
US6458147B1 (en) * 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
WO2003007845A1 (fr) * 2001-07-17 2003-01-30 Baxter International Inc. Compositions hemostatiques seches et procedes de preparation associes
US20030129730A1 (en) * 2001-11-15 2003-07-10 Abdellatif Chenite Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US20060258560A1 (en) * 2002-09-30 2006-11-16 Chunlin Yang Dry tissue sealant compositions
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
US20080187591A1 (en) * 2006-08-02 2008-08-07 Baxter International, Inc. Rapidly acting dry sealant and methods for use and manufacture

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
), Wallace et al., A Tissue Sealant Based on Reactive Multifunctional Polyethylene Glycol, J. Biomed Mater Res (Appl Biomater) 58:545-555, 2001 *
Chapter 10 of Biomaterials for Clinical Applications, Bhatia, pp 213-258 Springer, 2010 (first available 8/23/10) *
D.J.S. Hulmes, Chapter 2, Collagen Diversity, Synthesis and Assembly, in Collagen Structure and Mechanics, Fratzl, P., Ed. 2008 Springer *
David Brett, A Review of Collagen and Collagen-based Wound Dressings, Wounds 2008;20(12) *
Lecut et al., Fibrillar type I collagens enhance platelet-dependent thrombin generation via glycoprotein VI with direct support of alpha2betaI but not alphaIIbbeta3 integrin, Platelet and Blood Cells, 2005, pp. 107-114 *
Nektar Advanced PEGylation 2005-2006 Catalog, Nektar Therapeutics, 2005 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210001002A1 (en) * 2017-11-28 2021-01-07 Dalim Tissen Co., Ltd. Composition for hemostasis and container comprising same
US11628236B2 (en) * 2017-11-28 2023-04-18 Dalim Tissen Co., Ltd. Composition for hemostasis and container comprising same
EP3989875A4 (fr) * 2019-06-26 2023-07-26 Davol Inc. Matériaux hémostatiques pulvérulents secs réactifs comprenant un nucléophile et un agent de réticulation à base de polyéthylène glycol modifié multifonctionnel
CN114096285A (zh) * 2019-07-12 2022-02-25 加特技术公司 生物相容性柔性止血片
US12324866B2 (en) 2019-07-12 2025-06-10 Gatt Technologies B.V. Method for preparing a tissue-adhesive sheet
US12440600B2 (en) 2019-07-12 2025-10-14 Cilag Gmbh International Biocompatible, flexible, haemostatic sheet
US12070522B2 (en) 2020-02-18 2024-08-27 Ethicon, Inc. Melt blown dressing with gradient density
US12102722B2 (en) 2020-06-08 2024-10-01 Ethicon, Inc. Napped coated wound dressing
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US12151045B2 (en) 2020-12-28 2024-11-26 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CN115944771A (zh) * 2022-12-27 2023-04-11 合肥工业大学 一种具有强效湿粘附与止血功能的仿生止血糊剂及其制备方法

Also Published As

Publication number Publication date
JP6195569B2 (ja) 2017-09-13
AU2012318257B2 (en) 2015-10-01
MX356185B (es) 2018-05-17
WO2013053759A3 (fr) 2013-11-07
KR20140074992A (ko) 2014-06-18
KR102102002B1 (ko) 2020-04-20
CA2851321A1 (fr) 2013-04-18
IL231961A0 (en) 2014-05-28
EP4137165A1 (fr) 2023-02-22
MX2014004477A (es) 2015-09-10
CN103957949B (zh) 2017-07-18
JP2017124315A (ja) 2017-07-20
US20160136235A1 (en) 2016-05-19
EP2766059B1 (fr) 2022-11-23
WO2013053759A2 (fr) 2013-04-18
CN103957949A (zh) 2014-07-30
US9821025B2 (en) 2017-11-21
CA2851321C (fr) 2020-07-07
AU2012318257A1 (en) 2013-05-30
EP2766059A2 (fr) 2014-08-20
JP2014533988A (ja) 2014-12-18
ES2938568T3 (es) 2023-04-12

Similar Documents

Publication Publication Date Title
US9821025B2 (en) Hemostatic compositions
US10322170B2 (en) Hemostatic compositions
US12208176B2 (en) Process for making dry and stable hemostatic compositions
CA2851332C (fr) Composition hemostatique
CA2801120A1 (fr) Procede de fabrication de compositions hemostatiques sous forme seche et stable

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEDRICH, HANS CHRISTIAN;HOEFINGHOFF, JORIS;GORNA, KATARZYNA;SIGNING DATES FROM 20130115 TO 20130123;REEL/FRAME:029996/0611

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEDRICH, HANS CHRISTIAN;HOEFINGHOFF, JORIS;GORNA, KATARZYNA;SIGNING DATES FROM 20130115 TO 20130123;REEL/FRAME:029996/0611

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION